FHTX News & Events

Reports Q1 revenue $3.27M, consensus $7.94M. "Our lead program, FHD-909, continues to advance through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA4 mutations, where outcomes remain especially poor and deteriorate with later lines of therapy," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics. "At this year's American Association for Cancer Research Annual Meeting, we presented compelling preclinical data demonstrating the potential of FHD-909 in combination with an anti-PD-1 antibody to drive complete, durable tumor regression and anti-tumor immune memory."

Foghorn Therapeutics presented new preclinical data for Selective SMARCA2 inhibitor FHD-909 showing complete and durable tumor regression together with anti-tumor immune memory following combination treatment with an anti-PD-1 antibody in preclinical syngeneic mouse models. The company also reported new preclinical data for its Selective CBP and Selective EP300 degrader programs, demonstrating favorable efficacy and safety profiles across a range of difficult-to-treat cancers, in addition to progress with its Selective ARID1B degrader program. These data were unveiled in multiple oral and poster presentations at the 2026 American Association for Cancer Research Annual Meeting. Key highlights include: Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models; Selective CBP degrader FHT-171 shows strong anti-tumor activity and favorable tolerability in preclinical models of heavily pretreated ER+ breast cancer; Selective EP300 degrader outperforms clinical benchmark in preclinical multiple myeloma models, showing enhanced safety and efficacy ; Robust degradation achieved with cereblon-based selective ARID1B degraders with potential for oral bioavailability

Foghorn Therapeutics announced that Ryan Maynard will join the company as Chief Financial Officer, CFO, on February 23, 2026. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies. Prior to joining Foghorn, Maynard was most recently at Cara Therapeutics